[go: up one dir, main page]

PE20091262A1 - Compuestos de diarilhidantoina como antagonistas del receptor de androgeno - Google Patents

Compuestos de diarilhidantoina como antagonistas del receptor de androgeno

Info

Publication number
PE20091262A1
PE20091262A1 PE2008001821A PE2008001821A PE20091262A1 PE 20091262 A1 PE20091262 A1 PE 20091262A1 PE 2008001821 A PE2008001821 A PE 2008001821A PE 2008001821 A PE2008001821 A PE 2008001821A PE 20091262 A1 PE20091262 A1 PE 20091262A1
Authority
PE
Peru
Prior art keywords
compounds
androgen receptor
thioxo
oxo
phenyl
Prior art date
Application number
PE2008001821A
Other languages
English (en)
Inventor
Michael E Jung
Dongwon Yoo
Charles L Sawyers
Chris Tran
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PE20091262A1 publication Critical patent/PE20091262A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

REFERIDA A UN DERIVADO DE DIARILHIDANTOINA DE FORMULA (I), DONDE R1 Y R2 SON ALQUILO C1-C8, CICLOALQUILO C3-C20, ENTRE OTROS; R3 ES H, CN, FORMILO, IMIDAZOL, ENTRE OTROS; R4 ES H, F, Cl, Br, I; R11 Y R12 SON H O METILO. SON COMPUESTOS PREFERIDOS: 4-(3-(4-(3-CIANOPROPIL)FENIL)-4,4-DIMETIL-5-OXO-2-TIOXO-IMIDAZOLIDIN-1-IL)-2-(TRIFLUOROMETIL)BENZONITRILO, 4-(1-(4-(3-CIANOPROPIL)FENIL)-4-OXO-2-TIOXO-1,3-DIAZASPIRO[4,4]NON-3-IL)-2-TRIFLUOROMETILBENZONITRILO, 4-(8-OXO-5-(4-(4-OXOBUTIL)FENIL)-6-TIOXO-5,7-DIAZASPIRO[3.4]OCTAN-7-IL)-2-(TRIFLUOROMETIL)BENZONITRILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD ANTAGONISTA SOBRE EL RECEPTOR DE ANDROGENO (AR) Y SON UTILES EN EL TRATAMIENTO DEL CANCER DE PROSTATA REFRACTARIO A LA HORMONA
PE2008001821A 2007-10-26 2008-10-24 Compuestos de diarilhidantoina como antagonistas del receptor de androgeno PE20091262A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99607607P 2007-10-26 2007-10-26

Publications (1)

Publication Number Publication Date
PE20091262A1 true PE20091262A1 (es) 2009-09-09

Family

ID=40278902

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2008001821A PE20091262A1 (es) 2007-10-26 2008-10-24 Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
PE2012000638A PE20121470A1 (es) 2007-10-26 2008-10-24 Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
PE2017000081A PE20170428A1 (es) 2007-10-26 2008-10-24 Compuestos de diarilhidantoina

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2012000638A PE20121470A1 (es) 2007-10-26 2008-10-24 Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
PE2017000081A PE20170428A1 (es) 2007-10-26 2008-10-24 Compuestos de diarilhidantoina

Country Status (10)

Country Link
US (2) US8680291B2 (es)
EP (3) EP2620432A3 (es)
JP (4) JP5535925B2 (es)
AR (1) AR069039A1 (es)
CA (2) CA2966280A1 (es)
CL (1) CL2008003158A1 (es)
PE (3) PE20091262A1 (es)
TW (3) TWI557111B (es)
UY (1) UY31432A1 (es)
WO (1) WO2009055053A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US8110594B2 (en) 2006-03-29 2012-02-07 The Regents Of The University Of California Diarylthiohydantoin compounds
PE20091262A1 (es) * 2007-10-26 2009-09-09 Univ California Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
KR20110130439A (ko) 2009-02-24 2011-12-05 메디베이션 프로스테이트 테라퓨틱스 인코퍼레이티드 특정 디아릴히단토인 및 디아릴티오히단토인 화합물
US8710086B2 (en) * 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
WO2011029392A1 (en) * 2009-09-10 2011-03-17 Youzhi Tong Androgen receptor antagonists and uses thereof
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
PH12012501652A1 (en) 2010-02-16 2012-10-22 Aragon Pharmaceuticals Inc Androgen receptor modulators and uses thereof
MX2012009782A (es) 2010-02-24 2012-11-29 Medivation Prostate Therapeutics Inc Procesos para la sintesis de diariltiohidantoina y compuestos de diarilhidantoina.
CN102958364A (zh) * 2010-05-28 2013-03-06 德克萨斯大学系统董事会 低聚苯甲酰胺化合物及其用途
EP2646553A4 (en) * 2010-11-12 2015-01-07 Santaris Pharma As COMPOSITIONS AND METHODS OF TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCER
CN103608333B (zh) * 2011-03-10 2016-01-06 苏州开拓药业有限公司 雄激素受体拮抗剂及其用途
US8921378B2 (en) 2011-04-21 2014-12-30 Orion Corporation Androgen receptor modulating carboxamides
ES2696074T3 (es) 2011-07-29 2019-01-14 Medivation Prostate Therapeutics Llc Tratamiento del cáncer de mama
UY34646A (es) 2012-03-02 2013-10-31 Novartis Ag Compuestos de espirohidantoína y su uso como moduladores selectivos del receptor de andrógenos
PL2864291T3 (pl) 2012-06-26 2017-07-31 Bayer Pharma Aktiengesellschaft N-[4-(chinolin-4-yloksy)cykloheksylo(metylo)](hetero)arylokarboksyamidy jako antagoniści receptora androgenowego, ich wytwarzanie i zastosowanie jako produktów medycznych
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
AU2015360767A1 (en) 2014-12-12 2017-06-08 Medivation Prostate Therapeutics Llc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
CN106146403B (zh) * 2015-04-02 2018-11-20 正大天晴药业集团股份有限公司 一种恩杂鲁胺的纯化方法
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
EP3876929A1 (en) 2018-11-05 2021-09-15 Pfizer Inc. Combination for treating cancer
KR20230159510A (ko) 2021-03-24 2023-11-21 화이자 인코포레이티드 Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합
CN115181043B (zh) * 2022-07-27 2024-05-07 爱斯特（成都）生物制药股份有限公司 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US750351A (en) * 1904-01-26 Smoke-purifier
US756552A (en) * 1898-04-14 1904-04-05 Robert Adams Window-sash.
US680835A (en) * 1900-07-05 1901-08-20 Joseph A Beamisderfer Nut-lock.
US2004100A (en) 1934-05-25 1935-06-11 Carter Loran Everett Brush and stubble cutter
JPS4916937B1 (es) 1970-01-21 1974-04-25
JPS4920973B1 (es) 1970-05-28 1974-05-29
US3823240A (en) 1970-10-06 1974-07-09 Rhone Poulenc Sa Fungicidal hydantoin derivatives
JPS4887030U (es) 1972-01-27 1973-10-22
US3923994A (en) 1973-07-13 1975-12-02 Smithkline Corp Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity
GB1472467A (en) 1974-04-19 1977-05-04 Wyeth John & Brother Ltd Thiohydantoins
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
US3970662A (en) 1975-06-19 1976-07-20 Sterling Drug Inc. 4-(3-Nitrophenyl)-2,3,5,6-pyridinetetracarboxylic acid and intermediates
DE2614831A1 (de) 1976-04-06 1977-10-20 Bayer Ag 1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
MC1220A1 (fr) 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
CA1138334A (en) 1977-10-28 1982-12-28 Karl Bernauer Pharmaceutical preparations containing certain urea derivatives
DK543178A (da) 1977-12-01 1979-06-02 Wellcome Found Thiodydantoinderivater
EP0004723A1 (en) 1978-03-30 1979-10-17 Beecham Group Plc Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them
FR2449448B1 (fr) 1979-02-20 1983-05-27 Inst Nat Radio Elements Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation
FI801184A7 (fi) 1979-04-24 1981-01-01 F Hoffmann La Roche & Co Menetelmä imidatsolidiini-johdannaisten valmistamiseksi.
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57197268A (en) 1981-05-29 1982-12-03 Sumitomo Chem Co Ltd Substituted phenylhydantoin derivative, its preparation, and herbicide containing the same as active ingredient
US4753957A (en) 1981-09-28 1988-06-28 Rohm And Haas Company Substituted 2,4-imidazolidinediones and fungicidal compositions
DE3382406D1 (de) 1982-04-08 1991-10-17 Shell Int Research Neue hydantoine, ihre herstellung und verwendung.
US4432987A (en) 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
US4473393A (en) 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
JPS59210083A (ja) 1983-05-13 1984-11-28 Otsuka Chem Co Ltd １，３，４−チアジアゾ−ル−５−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS6092285A (ja) 1983-10-26 1985-05-23 Shionogi & Co Ltd イソオキサゾ−ル系環状尿素類
GB8513754D0 (en) 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
DE3604042A1 (de) 1986-02-08 1987-08-13 Hoechst Ag Imidazolidin(thi)on-derivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5084472A (en) 1986-11-04 1992-01-28 Roussel Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4859228A (en) 1987-07-16 1989-08-22 Ici Americas Inc Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
FR2619381B1 (fr) 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
CA1331757C (en) 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5614620A (en) 1988-03-30 1997-03-25 Arch Development Corporation DNA binding proteins including androgen receptor
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US6307030B1 (en) 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE3835168A1 (de) 1988-10-15 1990-04-19 Bayer Ag N-aryl-stickstoffheterocyclen, mehrere verfahren zu ihrer herstellung und ihre verwendung als herbizide
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
FR2656302B1 (fr) 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5346913A (en) 1992-05-26 1994-09-13 Rohm And Haas Company N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2715402B1 (fr) 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
CA2181358A1 (en) 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
AU3086095A (en) 1994-07-29 1996-03-04 Suntory Limited Imidazolidine derivative and use thereof
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
AU709345B2 (en) 1995-09-07 1999-08-26 Emory University Therapeutic azide compounds
DE19540027A1 (de) 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
FR2741346B1 (fr) 1995-11-16 1997-12-19 Roussel Uclaf Nouveau procede de preparation de derives phenylimidazolidine
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
WO1997019931A1 (en) 1995-11-28 1997-06-05 American Home Products Corporation 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives
US5554607A (en) 1995-11-28 1996-09-10 American Home Products Corporation Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
TW418195B (en) 1995-11-28 2001-01-11 American Home Prod 2-thioxo-imidazolidin-4-one derivatives
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US6489163B1 (en) 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
JP3697320B2 (ja) 1996-06-20 2005-09-21 株式会社日立製作所 光ファイバセンサ
US5726061A (en) 1996-10-08 1998-03-10 Smithkline Beechum Corporation Method of diagnosing and monitoring colorectal cancer
US7053263B2 (en) 1996-10-15 2006-05-30 The Regents Of The University Of California Mouse models of human prostate cancer progression
US7205437B2 (en) 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
DE69730416T2 (de) 1997-06-27 2005-09-08 Eads Deutschland Gmbh Füllstandmessradargerät
US6506607B1 (en) 1997-12-24 2003-01-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
AU4562799A (en) 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ATE240944T1 (de) 1998-09-22 2003-06-15 Degussa Verfahren zur herstellung von imidazolidin-2,4- dionen
US6673799B1 (en) 1998-09-22 2004-01-06 Yamanouchi Pharmaceutical Co. Ltd. Cyanophenyl derivative
WO2000026195A1 (en) 1998-10-30 2000-05-11 G.D. Searle & Co. Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6184249B1 (en) 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
WO2000044731A1 (en) 1999-01-27 2000-08-03 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
US6350763B1 (en) 1999-07-21 2002-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammation disease
WO2001030764A1 (en) 1999-10-22 2001-05-03 Takeda Chemical Industries, Ltd. 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
US6479063B2 (en) 1999-12-27 2002-11-12 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
EP1284973B1 (en) 2000-05-31 2007-06-27 Tanabe Seiyaku Co., Ltd. Inhibitors of alpha l beta 2 mediated cell adhesion
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
WO2002042488A1 (en) 2000-11-24 2002-05-30 Osmetech Plc Detection of infections in liquid samples by detecting fatty acids present in the headspace associated with the liquid sample
ATE440096T1 (de) 2000-12-08 2009-09-15 Takeda Pharmaceutical Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung
WO2002053155A1 (en) 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
CN1596253A (zh) 2001-10-01 2005-03-16 布里斯托尔-迈尔斯斯奎布公司 用作抗炎药的螺－乙内酰脲化合物
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
GB0200283D0 (en) 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
EP1476419B1 (en) 2002-02-08 2006-02-01 Merck & Co., Inc. N-biphenylmethyl aminocycloalkanecarboxamide derivatives
DE10218963A1 (de) 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
TW200401638A (en) 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
AU2003262717A1 (en) 2002-08-15 2004-03-03 Genzyme Corporation Brain endothelial cell expression patterns
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
US20060025589A1 (en) 2002-10-01 2006-02-02 Jean Binet 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes
FR2845384B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
DE10322108B4 (de) 2003-05-09 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
JP4664814B2 (ja) 2003-06-12 2011-04-06 中外製薬株式会社 イミダゾリジン誘導体
BRPI0411255A (pt) 2003-06-12 2006-08-01 Novo Nordisk As composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
WO2005037797A1 (en) 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
EP1709152A4 (en) 2003-12-15 2007-11-07 Univ California MOLECULAR SIGNATURE OF PTEN TUMOR SUPPRESSOR
NZ548209A (en) 2003-12-19 2009-07-31 Univ California Methods and materials for assessing prostate cancer thearapies
US7173044B2 (en) 2004-02-19 2007-02-06 Solvay Pharmaceuticals B.V. Imidazoline derivatives having CB1-antagonistic activity
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
JP2007529533A (ja) 2004-03-15 2007-10-25 ピーティーシー セラピューティクス，インコーポレーテッド 血管新生の抑制に有用なテトラサイクリックカルボリン誘導体
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
DE602005027213D1 (de) 2004-08-03 2011-05-12 Chugai Pharmaceutical Co Ltd Neue imidazolidinderivate
EP1790640A4 (en) * 2004-09-09 2009-07-29 Chugai Pharmaceutical Co Ltd NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF
RS53967B1 (sr) * 2005-05-13 2015-08-31 The Regents Of The University Of California Diaril hidantoin jedinjenja kao antagonisti receptora androgena za lečenje raka
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
JP4887030B2 (ja) 2005-11-18 2012-02-29 株式会社日立ハイテクノロジーズ 荷電粒子線装置
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
DK3100727T3 (en) 2006-03-27 2018-11-12 Univ California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US8110594B2 (en) * 2006-03-29 2012-02-07 The Regents Of The University Of California Diarylthiohydantoin compounds
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
PE20091262A1 (es) * 2007-10-26 2009-09-09 Univ California Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
BRPI0821611A8 (pt) 2007-12-11 2016-12-13 Theravance Inc Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu
US20110130296A1 (en) 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
KR20110130439A (ko) 2009-02-24 2011-12-05 메디베이션 프로스테이트 테라퓨틱스 인코퍼레이티드 특정 디아릴히단토인 및 디아릴티오히단토인 화합물
US8710086B2 (en) 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
US8507195B2 (en) 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
MX2012009782A (es) 2010-02-24 2012-11-29 Medivation Prostate Therapeutics Inc Procesos para la sintesis de diariltiohidantoina y compuestos de diarilhidantoina.

Also Published As

Publication number Publication date
WO2009055053A2 (en) 2009-04-30
EP2220050A2 (en) 2010-08-25
US9896437B2 (en) 2018-02-20
JP2015180672A (ja) 2015-10-15
TWI557111B (zh) 2016-11-11
UY31432A1 (es) 2009-05-29
US20150065546A1 (en) 2015-03-05
TW200934762A (en) 2009-08-16
PE20121470A1 (es) 2012-11-18
JP2011500813A (ja) 2011-01-06
US20090111864A1 (en) 2009-04-30
TW201716385A (zh) 2017-05-16
TW201522315A (zh) 2015-06-16
EP2397469B1 (en) 2014-12-31
JP5535925B2 (ja) 2014-07-02
JP2017052796A (ja) 2017-03-16
US8680291B2 (en) 2014-03-25
EP2620432A2 (en) 2013-07-31
TWI469971B (zh) 2015-01-21
CA2703635C (en) 2017-06-27
JP5914538B2 (ja) 2016-05-11
CA2703635A1 (en) 2009-04-30
AR069039A1 (es) 2009-12-23
EP2620432A3 (en) 2013-12-18
CA2966280A1 (en) 2009-04-30
CL2008003158A1 (es) 2009-05-29
HK1165198A1 (en) 2012-09-28
EP2397469A1 (en) 2011-12-21
WO2009055053A3 (en) 2009-06-11
JP2014074070A (ja) 2014-04-24
PE20170428A1 (es) 2017-05-14

Similar Documents

Publication Publication Date Title
PE20091262A1 (es) Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
PE20091653A1 (es) Derivados sustituidos de pirazol y su uso
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
PE20070720A1 (es) Derivados de fenilo como antagonistas del receptor 3 de la histamina
PE20090160A1 (es) COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
MY150136A (en) Picolinamide derivatives as kinase inhibitors
PE20091370A1 (es) Arilpirrolinas insecticidas
PE20091493A1 (es) Inhibidores de quinasa de pirrolopirazina
PE20121559A1 (es) Compuestos de benzoxepina inhibidores de la p13k
CU23784B7 (es) Bencimidazoles sustituidos como inhibidores de cinasa
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
DE602005016162D1 (de) Benzimidazolderivate und ihre Verwendung als AII Rezeptor-Antagonist
PE20090718A1 (es) Derivados de espiroindolinona
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
NZ603525A (en) Pyrimidine based compound and uses thereof
ATE555099T1 (de) Dual wirkende benzimidazol-derivate und deren verwendung als blutdrucksenkende mittel
PE20121045A1 (es) Agonista de gpr119
PE20090279A1 (es) Derivados de 3,3-espiroindolinona como agentes antagonistas de mdm2
PE20140858A1 (es) Derivados de piperidina como inhibidores de renina
NZ601077A (en) Use of an adrenal hormone-modifying agent
CL2011000625A1 (es) Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida.
AR065714A1 (es) Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida
NZ612221A (en) Ectoparasiticidal active substance combinations
PE20091032A1 (es) Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan)

Legal Events

Date Code Title Description
FC Refusal